Anti-pad2 antibody for treating and evaluating rheumatoid arthritis

Inactive Publication Date: 2018-10-04
THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0006]A PAD2 ELISA assay was established to screen for anti-PAD2 IgG in sera from RA patients and healthy controls. The clinical and demographic characteristics of RA patients were compared according to their anti-PAD2 antibody status and level. Multivariable models were constructed to explore the independent associations of anti-PAD2 antibodies with clinical variables. The frequency of anti-PAD2 antibodies in RA patients was 18.5%, and the median anti-PAD2 antibody level was 75% higher in RA patients compared with control individuals (p=0.0012). Among RA patients, anti-PAD2 antibodies were inversely associated with HLA-DRβ1 shared epitope alleles, swollen joi

Problems solved by technology

There is marked heterogeneity in the clinical presentation, disease course, involvement of extra-articular organs, and response to therapy observed among individuals with RA, but the mechanisms driving this diversity are poorly

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-pad2 antibody for treating and evaluating rheumatoid arthritis
  • Anti-pad2 antibody for treating and evaluating rheumatoid arthritis
  • Anti-pad2 antibody for treating and evaluating rheumatoid arthritis

Examples

Experimental program
Comparison scheme
Effect test

Example

EXAMPLE

[0070]Autoantibodies to Peptidylarginine Deiminase 2 are Associated with Less Severe Disease in Rheumatoid Arthritis

[0071]In this study, we found that anti-PAD2 antibodies are present in a subset of patients with RA who lack the traditional risk factors associated with severe disease, such as ACPAs and SE. Instead, they have a unique set of demographic and clinical characteristics including less progressive articular damage and lower risk of ILD. These findings have important implications in the ability to identify clinically informative patient subgroups to aid in disease prognosis and selection of appropriate therapeutic agents.

Methods

[0072]Human Subjects

[0073]Convenience sera from 37 healthy controls and 42 patients with RA from the Johns Hopkins Arthritis Center were used as a discovery sample for anti-PAD2 antibodies. Sera from 184 RA patients from the Evaluation of Subclinical Cardiovascular Disease and Predictors of Events in Rheumatoid Arthritis (ESCAPE RA) cohort wer...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A method for obtaining a prognosis for a subject having rheumatoid arthritis by measuring the levels of anti-PAD2 antibodies is described. Methods of using anti-PAD2 antibodies to treat rheumatoid arthritis are also described.

Description

CONTINUING APPLICATION DATA[0001]This application claims the benefit of U.S. Provisional Application Ser. No. 62 / 481,158, filed Apr. 4, 2017, the disclosure of which is incorporated by reference herein.GOVERNMENT FUNDING[0002]This invention was made with government support under grant number NIH NIAMS AR050026-10 awarded by the National Institutes of Health. The government has certain rights in this invention.BACKGROUND[0003]Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by immune-mediated damage of synovial joints that affects approximately 1% of the population. There is marked heterogeneity in the clinical presentation, disease course, involvement of extra-articular organs, and response to therapy observed among individuals with RA, but the mechanisms driving this diversity are poorly understood. Anti-citrullinated protein antibodies (ACPAs), detected by the anti-cyclic citrullinated peptide (CCP) assay, are hallmark serologic features of patients with RA...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/395A61P29/00A61P37/06A61P19/02G01N33/564A61K39/00
CPCA61K39/0008A61P19/02A61P29/00A61P37/06A61K39/39533G01N33/564G01N2800/52C07K16/40C12Y305/03015G01N2800/50G01N2800/7095C07K2317/24G01N2333/978G01N2800/24C07K2317/76
Inventor DARRAH, ERIKA L.ANDRADE, FELIPE
Owner THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap